Recombinant Mouse CD55/DAF Protein, CF

Catalog #: 5490-CD
1 Citation Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
5490-CD-050

R&D Systems Recombinant Proteins and Enzymes

1 Image

Product Details

Citations (1)

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Mouse CD55/DAF Protein, CF Summary

Product Specifications

Purity

>90%, by SDS-PAGE under reducing conditions and visualized by silver stain

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. When rmCD55 is immobilized at 0.5 μg/mL, 100 μL/well, the concentration of rmCD97 that produces 50% of the optimal binding response is found to be approximately
0.15-0.5 μg/mL.

Source

Mouse myeloma cell line, NS0-derived mouse CD55/DAF protein
Asp35-Pro359, with a C-terminal Asp-Ile and 6-His tag

Accession #

Q61475

N-terminal Sequence
Analysis

Asp35

Predicted Molecular Mass

36.6 kDa

SDS-PAGE

50-65 kDa, reducing conditions

Product Datasheets

5490-CD

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

5490-CD

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 100 μg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reconstitution Calculator

Background: CD55/DAF

CD55, also known as DAF or decay-accelerating factor, is a 70 - 75 kDa member of the RCA family of proteins. Human RCA (regulators of complement/C' activation) proteins are products of chromosome 1 genes that are ubiquitously expressed on cells exposed to plasma complement proteins (1 - 4). A hallmark of RCA proteins is the presence of 4 to 30 SCRs (short consensus repeats; also called CCPs for C' control protein modules) in their plasma-exposed regions. SCRs are characterized by a 60 - 65 amino acid (aa) module that contains a highly conserved Trp residue and two internal disulfide bonds that create a beta -barrel structure (1). Human CD55 is synthesized as a 381 aa precursor that contains a 34 aa signal sequence, a 319 aa mature region and a 28 aa C-terminal prosegment (5, 6). The mature region contains four SCR modules and a C-terminal O-glycosylated extension (7). Following cleavage of the prosegment, a serine is exposed that serves as an anchor for a GPI-linkage (8). Multiple polymorphisms are found in the molecule. Alternate splicing also exists. One form that may not be translated shows an intron insertion in the prosegment, resulting in a 79 aa substitution for the standard C-terminal 20 aas of the prosegment (6). Another form generates a truncated 199 aa precursor that cannot be membrane-bound and may not be secreted (9). Mature CD55 is 53% and 84% aa identical to mouse and monkey CD55, respectively. CD55 is known to bind CD97 via the first SCR (4). It also binds physiologically-generated C3 convertases with its second and third SCRs (7, 10). Binding results in an accelerated "decay", or dissociation of active C3 convertases, thus blocking the development of C' attack complexes on nonforeign cells (1, 2). Viruses and bacteria are also known to utilize multiple SCR sites for infection (4, 11). Finally, CD55 is broadly expressed in malignant tumors (12 - 13). Here, CD55 is involved in the promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, autocrine loops for cell rescue and evasion of apoptosis, neoangiogenesis, invasiveness, cell motility, and metastasis via oncogenic tyrosine kinase pathway activation and CD97 binding (12 - 13).

References

Herbert, A. et al. (2002) Biochem. Soc. Trans. 30:990.
Miwa, T. and W-C. Song (2001) Int. Immunopharm. 1:445.
Hourcade, D. et al. (2000) Immunopharm. 49:103.
Lea, S. (2002) Biochem. Soc. Trans. 30:1014.
Medof, M.E. et al. (1987) Proc. Natl. Acad. Sci. USA 84:2007.
Caras, I.W. et al. (1987) Nature 325:545.
Lukacik, P. et al. (2004) Proc. Natl. Acad. Sci. USA 101:1279.
Moran, P. et al. (1991) J. Biol. Chem. 266:1250.
Lublin, D.M. et al. (1994) Blood 84:1276.
Williams, P. et al. (2003) J. Biol. Chem. 278:10691.
Hafenstein, S. et al. (2007) J. Virol. 81:12927.
Mikesch, J.H. et al. (2006) Biochem. Biophys. Acta. 1766:42.
Mikesch, J.H. et al. (2006) Cell. Oncol. 28:223.

Entrez Gene IDs

1604 (Human); 13136 (Mouse)

Alternate Names

CD55 antigen; CD55 molecule, decay accelerating factor for complement (Cromer blood group); CD55; CR; CRdecay accelerating factor for complement (CD55, Cromer blood group system); CROMDAFcomplement decay-accelerating factor; DAF; decay accelerating factor for complement; TC

Related Research Areas

Complement Pathway

Citation for Recombinant Mouse CD55/DAF Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

1 Citation: Showing 1 - 1